No headlines found.
PRNewswire (Tue, 19-Mar 8:15 AM ET)
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders.
Seelos Therapeutics trades on the NASDAQ stock market under the symbol SEEL.
As of April 23, 2024, SEEL stock price climbed to $0.33 with 302,696 million shares trading.
SEEL has a beta of 3.18, meaning it tends to be more sensitive to market movements. SEEL has a correlation of 0.03 to the broad based SPY ETF.
SEEL has a market cap of $3.23 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, SEEL stock traded as high as $198.00 and as low as $.32.
The top ETF exchange traded funds that SEEL belongs to (by Net Assets): PSIL, VTI, VXF.
SEEL has underperformed the market in the last year with a price return of -98.4% while the SPY ETF gained +24.4%. SEEL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -74.2% and -35.5%, respectively, while the SPY returned +5.0% and -2.4%, respectively.
SEEL support price is $.30 and resistance is $.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SEEL stock will trade within this expected range on the day.